Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool August 9, 2007 Brian Orelli	Acquisition Raises Barr Half a year after acquiring a giant competitor, Barr Pharmaceuticals results appear to be on track to increase year-over-year revenues.
The Motley Fool February 21, 2008 Brian Orelli	Watson Gets Less Generic Branded sales were up while generics fell for the year, which made Watson Pharmaceutical a more balanced company.
The Motley Fool May 14, 2007 Brian Lawler	Mylan Goes on a Drug Binge The generic drugmaker makes a hefty acquisition, but it's hard to say at this point how good of a deal this is for shareholders.
The Motley Fool November 3, 2010 Brian Orelli	Teva's New Drugs Pay Off The generic-drug maker keeps generating big profits.
The Motley Fool August 3, 2004 Jeff Hwang	Generics Pump Watson The firm's strong growth in generic drug sales eases its branded product pains. The stock is up more than 10%.
The Motley Fool October 16, 2006 Brian Lawler	The Coming Generic Drug Boom Generic drugmakers are poised to profit from several key factors. Investors, take note.
The Motley Fool November 10, 2006 Brian Lawler	Watson Doesn't Wow Investors The generic drug developer made a $2 billion buyout of smaller competitor Andrx and finally closed the deal this quarter. Investors, take note.
The Motley Fool February 28, 2007 Brian Lawler	Worrisome Watson The maker of generic drugs could have a challenging year ahead. Investors, take note.
The Motley Fool June 28, 2004 Jeff Hwang	Watson Pharmaceuticals Tumbles The generic drug business at Watson Pharmaceuticals is still going strong; it's the branded products that are causing trouble.
The Motley Fool January 31, 2007 Brian Lawler	Mylan on the Generic Attack Two new drug approvals for the generic drugmaker come in the midst of a changing regulatory environment. Investors, take note.
The Motley Fool July 1, 2008 Brian Orelli	As the FDA Generics Office Turns The FDA reluctantly gives Teva a 180-day exclusive period to sell generic Risperdal.
The Motley Fool May 28, 2008 Brian Orelli	A Rough Quarter for Generic-Drug Makers Investors rocked the smaller companies the most.
The Motley Fool October 29, 2007 Brian Orelli	The Extended Release That Wasn't The FDA is investigating Teva's generic version of Wellbutrin XL. Investors, take note.
The Motley Fool March 13, 2006 Stephen D. Simpson	Watson Pays Up to Stay in the Game Watson gets bigger, but how much better? The company is buying Andrx for $25 a share. Investors, take note.
The Motley Fool December 28, 2006 Brian Lawler	Pliva's Late Christmas Gift to Barr Normally generic drug competitors, Barr Pharmaceuticals and Par Pharmaceutical Companies announced the launch of a generic version of GlaxoSmithKline's drug, Zofran. Investors, take note.
The Motley Fool May 21, 2007 Brian Orelli	The Doctor Is on a Roller Coaster This quarter marks the end of the fiscal year for Dr. Reddy's, so investors should keep an eye out for the annual report. It should give a more complete picture of the road ahead.
Chemistry World August 20, 2012	Generic Actos Approved Three generics manufacturers - Mylan, Ranbaxy and Teva - have won US marketing approval for their generic versions of Actos diabetes tablets.
The Motley Fool October 29, 2007 Brian Orelli	Foolish Forecast: Tenacious Teva The generic drug maker releases earnings shortly. Here's a look at whether investors should expect a generic quarter or a blockbuster.
The Motley Fool May 9, 2006 Stephen D. Simpson	Will Par Stay in the Fairway? Par Pharmaceutical is relatively unloved; does that mean opportunity or inferiority for investors?
The Motley Fool January 23, 2007 Brian Lawler	No Generic Profit for Reddy Investors looking to hedge a pharmaceutical position in case of adverse congressional legislation (or those looking for an international company in booming India) might do well to look at Dr. Reddy's.
The Motley Fool July 27, 2009 Brian Orelli	Mylan Ruins It for Everyone If customers begin to mistrust generic drugs from Mylan or whoever -- fearing that the companies are putting profits above safety -- all generic-drug companies will be hurt.
The Motley Fool July 27, 2010 Brian Orelli	Branded? Generic? They're Both Doing Great! Teva Pharmaceuticals registers strong growth on both fronts.
The Motley Fool August 28, 2007 Brian Orelli	Teva Gets a Two-For Even for a maker of generic drugs, getting two FDA drug approvals in as many business days is a feat not often seen. Teva Pharmaceuticals managed to do it, though. Investors, take note.
The Motley Fool July 24, 2007 Brian Orelli	A Generic Roller Coaster After being up last quarter, sales at Dr. Reddy's Laboratories plummet this quarter. Will they ride to another peak?
The Motley Fool March 3, 2010 Brian Orelli	Judge's Ruling Has Brand and Generic Drugmakers Smiling A ruling on the patents on Merck's blood pressure medications Cozaar and Hyzaar benefited both Merck and the plaintiff in the suit, generic-drug maker Teva Pharmaceuticals. The defendant in the suit wasn't actually Merck but the Food and Drug Administration.
The Motley Fool May 29, 2007 Brian Lawler	One Final Look at the Old Mylan With the Merck acquisition not expected to be accretive to earnings for at least two years, the question is if Mylan leveraged its financial health too far in its quest to get bigger and keep up in this buyout race.
The Motley Fool May 12, 2011 Brian Orelli	Teva's Mixed Bag Diversification sure helps.
The Motley Fool August 8, 2008 Rich Duprey	Barr Hits a Home Run Barr gets to market Bayer's authorized generic version of contraceptive Yasmin without fear of competition for at least 180 days -- giving them a huge competitive edge over rivals.
The Motley Fool October 31, 2007 Brian Orelli	From Apples to Apple Pie at Teva Year-over-year sales skyrocket at Teva Pharmaceutical, due to the launch of more than 25 new products. Investors, take note.
The Motley Fool December 17, 2007 Brian Orelli	Barr Labs' Legal Tables Turned Barr Labs announces that is suing both Watson Pharmaceuticals and Novartis' generic subsidiary Sandoz for patent infringement regarding Barr's SEASONALE extended-cycle birth control pill.
The Motley Fool June 27, 2007 Billy Fisher	Improving Morale at Barr Preliminary OK of Barr Pharmaceutical's generic antidepressant perks up the stock's potential.
The Motley Fool June 22, 2006 Stephen D. Simpson	Merck Goes on the Attack Predator becomes prey in this latest twist in the generics game. Given how much the markets hate uncertainty, that could mean that big generic drug companies might go on sale for patient long-term investors.
The Motley Fool October 25, 2007 Brian Orelli	Reddy for a Rollercoaster Ride In their quarterly results Dr. Reddy's Laboratories sees a dip in revenue from the loss of authorized generics.
The Motley Fool September 30, 2011 Brian Orelli	When You Need More Than Just a Low-Margin Business Teva Pharmaceuticals, arguably the largest generic-drug maker, can use economies of scale more easily than smaller companies like Watson Pharmaceuticals or Par Pharmaceutical, but it's still pushing further into branded drugs.
The Motley Fool February 7, 2006 Stephen D. Simpson	Barr None Bargain hunters are probably going to come up short when it comes to assessing Barr Pharmaceuticals' stock, but a fairly rich package of opportunities should keep growth strong for the immediate future.
The Motley Fool May 12, 2004 Phil Wohl	Mylan's Big Break? The maker of generic pimple cream wants to lead the pack. Can it?
The Motley Fool February 29, 2008 Brian Orelli	Barred by Debt The picture continues to look bleak at Barr Labs, due to debt taken on to acquire Pliva in 2006.
The Motley Fool February 28, 2008 Brian Lawler	Benefiting From 2008's Generic Drugs While drug companies scramble to make up for lost revenue as their products are hit with patent expirations, other companies will benefit from the patent losses. Take a look at some winners and losers of drugs going off patent this year.
The Motley Fool December 20, 2011 Brian Orelli	If You Can't Beat 'Em, Join 'Em: Amgen Goes Generic Biosimilars are coming -- might as well get a piece of the action.
The Motley Fool July 18, 2008 Rich Duprey	More Group Therapy From Generics The Teva deal for Barr shows consolidation is still underway in the industry.
The Motley Fool December 29, 2009 Brian Orelli	Some Brand-Name Patents: Going, Going, Gone in 2010 Generic drug competition is coming for Lipitor, Plavix, and others.
The Motley Fool November 8, 2006 Brian Lawler	Barr's Wounded Quarter If your revenues live by the generic sword, they can die by it, too. That seems to be the case today for Barr Pharmaceuticals. Investors, take note.
The Motley Fool November 26, 2008 Brian Orelli	Watson Gets Some Hand-Me-Downs Much like discount stores, generic-drug makers are in a cutthroat low-margin business, where "larger" almost always means "better."
The Motley Fool May 16, 2007 Rich Duprey	Mylan's Costly Bid to Capture the Flag Its winning bid for a German Merck unit might be why it's falling behind in the generics game. Investors, take note.
Chemistry World October 8, 2012 Phillip Broadwith	Europe gives generics merger the green flag Two of the top five global generic medicines manufactures, Watson and Actavis, have been given the go-ahead to merge by the European Commission.
The Motley Fool February 23, 2007 Rich Duprey	Foolish Forecast: Barr Labs Resets Bar The pharmaceutical is set to release fourth-quarter 2006 financial results. Investors, here is what you can expect to see.
Pharmaceutical Executive October 1, 2005 Glass & Worrell	Whose Afraid of Authorized Generics Losing a patent challenge lets a generic competitor grab market share and slash branded profits. Sound scary? Ignoring authorized generics is worse.
The Motley Fool April 14, 2008 Brian Orelli	Teva Gets What It Wants Teva persuades a court to order the FDA to award it a marketing exclusivity for generic Risperdal.
The Motley Fool October 26, 2011 Brian Orelli	Momenta Stopped. Again. Oh, no - an authorized generic gets launched.
The Motley Fool May 17, 2007 Rich Duprey	Foolish Forecast: My, Oh, Mylan The generic drug maker is set to report fourth-quarter 2007 financial results: Investors face the prospect of shareholder dilution, a cut in its credit rating, and the suspension of its dividend.